Route of epoetin administration influences hemoglobin variability in hemodialysis patients

American Journal of Nephrology

Volumn 29, Issue 6, 2009, Pages 532-537

  Patel, Tejas ^b   Hirter, Angie ^a   Kaufman, James ^c   Keithi Reddy, Sai Ram ^b   Reda, Domenic ^a   Singh, Ajay ^b  

^a HINES VA HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Anemia; Bundling of dialysis service; Hemoglobin variability; Subcutaneous epoetin

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

AGED; ANEMIA; COHORT STUDIES; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 57649100605     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187649     Document Type: Article

References (15)

1. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
2. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3: 133-138.
3. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:316 4-3170.
4. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, Feldman HI: Historyadjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008;3:777-782.
5. Fishbane S, Berns JS: Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007;22:2129-2132.
6. Besarab A: Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration. Am J Kidney Dis 1993;22: 13-22.
7. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-583.
8. Http://thomas.Loc.Gov/cgi-bin/query/ f?C110:8:./temp/∼c110acfglu: E1131 (accessed August 27, 2008).
9. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343.
10. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-124.
11. Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM: Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Clin Nephrol 1999;51: 367-372.
12. Salmonson T, Danielson BG, Wikstrom B: The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990;29: 709-713.
13. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210.
14. Hynes DM, Stroupe KT, Greer JW, Reda DJ, Frankenfield DL, Kaufman JS, Henderson WG, Owen WF, Rocco MV, Wish JB, Kang J, Feussner JR: Potential cost savings of erythropoietin administration in end-stage renal disease. A m J Med 2002;112:169-175.
15. Knauss MD, Walton T, Macon EJ: Switching from i.v. to s.c. epoetin in hemodialysis patients. Am J Health Syst Pharm 2002;59: 1783-1784.